Infinity Pharmaceuticals Inc (INFI)

2.36
NASDAQ : Health Care
Prev Close 2.36
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.84 / 6.96
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 49.73M
Market Cap 120.35M
EPS -2.60
P/E Ratio 0.56
Div & Yield N.A. (N.A)

Latest News

Infinity Presents Preclinical Data And Phase 1 Clinical Data On IPI-549 At PI3K Keystone Symposia Conference

Infinity Presents Preclinical Data And Phase 1 Clinical Data On IPI-549 At PI3K Keystone Symposia Conference

- Inhibition of PI3K-Gamma by IPI-549 Can Overcome Tumor Resistance to Checkpoint Inhibitors in Preclinical Models -

Dow Needs to Hit 20K to Shake Things Up

Market has fallen into a dull pattern.

Infinity Provides 2017 Goals And Financial Guidance

Infinity Provides 2017 Goals And Financial Guidance

- Updated Data From Phase 1 Study of IPI-549, an Immuno-Oncology Development Candidate Targeting PI3K-Gamma, Anticipated in 2017 -

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.

Infinity Announces Organizational Changes

Infinity Announces Organizational Changes

-- Lawrence Bloch Promoted to President --

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Wynn Resorts and Virtu Financial -- have been scooping up shares of their own stock lately.

Notable Friday Option Activity: INFI, RSO, P

Notable Friday Option Activity: INFI, RSO, P

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Infinity Pharmaceuticals Inc , where a total volume of 7,196 contracts has been traded thus far today, a contract volume which is representative of approximately 719,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 130.3% of INFI's average daily trading volume over the past month, of 552,295 shares.

Infinity Announces Second Publication On PI3K-Gamma In Nature

Infinity Announces Second Publication On PI3K-Gamma In Nature

-- Inhibition of PI3K-Gamma by IPI-549 Can Reverse Tumor Resistance to Checkpoint Inhibitors in Preclinical Models --

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors

-- Evaluation of IPI-549 as a Monotherapy Continuing, with Combination Portion of Phase 1 Study Expected to Begin This Fall --

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem's Pipeline

Short Interest Jumps 24.6% For INFI

Short Interest Jumps 24.6% For INFI

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 408,920 share increase in total short interest for Infinity Pharmaceuticals Inc , to 2,067,803, an increase of 24.65% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.

Infinity Announces Publication On PI3K-Gamma In Nature

Infinity Announces Publication On PI3K-Gamma In Nature

- PI3K-Gamma Identified as a Critical Molecular Switch that Controls Immune Suppression -

Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration

Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration

- Infinity to Explore Strategic Options for Duvelisib Program to Support Global Regulatory Filings for Duvelisib -

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate

Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint

Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint

Analysts cut valuation estimates for Infinity Pharmaceuticals after a disappointing drug study.

Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study

Analysts cut valuation estimates after a disappointing drug study.